T淋巴细胞亚群、IL-6在胃癌患者中的表达及其与预后的相关性

doi:10.3760/cma.j.issn.1007-1245.2024.15.024

摘要/Abstract

摘要：

目的　分析外周血T淋巴细胞亚群及白细胞介素-6（interleukin-6，IL-6）在胃癌患者中的表达，探究其与预后的相关性。方法　选取2021年6月至2023年6月连云港市第二人民医院收治的106例胃癌患者为试验组，入院次日检测其外周血T淋巴细胞亚群（CD3⁺、CD4⁺、CD8⁺）及IL-6水平。选取同时段于连云港市第二人民医院进行体检的健康者80例为对照组，体检当日检测其外周血T淋巴细胞亚群及IL-6水平。比较两组T淋巴细胞亚群及IL-6水平。胃癌患者院外随访6个月，根据患者死亡、存活情况将其分为预后不良组（17例）、预后良好组（89例）。预后不良组男10例（58.82%），女7例（41.18%），年龄（60.47±5.89）岁；文化程度：中学及以上9例（52.94%），中学以下8例（47.06%）。预后良好组男55例（61.80%），女34例（38.20%），年龄（60.08±5.71）岁；文化程度：中学及以上32例（35.96%），中学以下57例（64.04%）。logistic回归分析影响胃癌患者预后的因素。采用受试者操作特征曲线（ROC）评估外周血T淋巴细胞亚群及IL-6预测胃癌患者预后的价值。采用t检验和χ²检验。结果　试验组CD3⁺、CD4⁺水平低于对照组［（55.27±8.72）%比（68.97±6.45）%、（26.42±10.21）%比（38.12±5.07）%］，CD8⁺、IL-6水平高于对照组［（33.36±6.02）%比（24.66±3.75）%、（6.97±3.29）ng/L比（3.62±1.01）ng/L］，差异均有统计学意义（t=-11.821、-9.413、11.360、8.803，均P<0.05）。预后不良组CD3⁺、CD4⁺水平低于预后良好组［（45.12±10.06）%比（57.21±6.97）%、（20.01±10.12）%比（27.64±9.81）%］，CD8⁺、IL-6水平、肿瘤分期Ⅳ期患者占比高于预后良好组［（40.12±6.01）%比（32.07±5.12）%、（9.75±3.16）ng/L比（6.44±3.05）ng/L、70.59%（12/17）比32.58%（29/89）］，差异有统计学意义（t=-6.068、-2.924、5.774、4.077，χ²=8.692，均P<0.05）。logistic回归分析显示，肿瘤分期、CD3⁺、CD8⁺、IL-6水平是影响胃癌患者预后的因素（均P<0.05）。CD3⁺、CD8⁺、IL-6预测患者预后不良的ROC下面积分别为0.847、0.853、0.768。结论　胃癌患者CD3⁺、CD4⁺低表达，CD8⁺及IL-6高表达。CD3⁺、CD8⁺、IL-6水平是影响胃癌患者预后的因素。

关键词:

胃癌, 外周血T淋巴细胞亚群, 白细胞介素-6, 预后

Abstract:

Objective　To analyze the expression of peripheral blood T lymphocyte subsets and interleukin-6 (IL-6) in patients with gastric cancer, and to explore their correlation with prognosis. Methods　A total of 106 patients with gastric cancer treated at Lianyungang Second People's Hospital from June 2021 to June 2023 were selected as an experimental group, and their peripheral blood T lymphocyte subsets (CD3⁺, CD4⁺, and CD8⁺) and IL-6 levels were detected the day after they were admitted to the hospital. Eighty healthy people who came to the hospital for physical examination at the same time were selected as a control group, and their peripheral blood T lymphocyte subsets and IL-6 levels were detected on the day of physical examination. The T lymphocyte subsets and IL-6 levels were compared between the two groups. The patients were followed up 6 months after discharge, and were divided into a poor prognosis group (17 cases) and a good prognosis group (89 cases) according to death and survival. There were 10 males (58.82%) and 7 females (41.18%) in the poor prognosis group; they were (60.47±5.89) years old; 9 cases' (52.94%) education level was middle school or above, and 8 cases' (47.06%) below middle school. In the good prognosis group, there were 55 males (61.80%) and 34 females (38.20%); they were (60.08±5.71) years old; 32 cases' (35.96%) education level was middle school or above, and 57 cases' (64.04%) below middle school. The logistic regression analysis was done for the prognostic factors in the patients. The receiver operating characteristic curves (ROC) were drawn to evaluate the values of peripheral blood T lymphocyte subsets and IL-6 in the prediction of the patients' prognosis. t and χ² were applied. Results　The levels of CD3⁺ and CD4⁺ in the experimental group were lower than those in the control group [(55.27±8.72)% vs. (68.97±6.45)% and (26.42±10.21)% vs. (38.12±5.07)%]; the levels of CD8⁺ and IL-6 in the experimental group were higher than those in the control group [(33.36±6.02)% vs. (24.66±3.75)% and (6.97±3.29) ng/L vs. (3.62±1.01) ng/L]; there were statistical differences (t=-11.821, -9.413, 11.360, and 8.803; all P<0.05). The levels of CD3⁺ and CD4⁺ in the poor prognosis group were lower than those in the good prognosis group [(45.12±10.06)% vs. (57.21±6.97)% and (20.01±10.12)% vs. (27.64±9.81)%]; the levels of CD8⁺ and IL-6 and the proportion of the patients of tumor stage Ⅳ in the poor prognosis group were higher than those in the good prognosis group [(40.12±6.01)% vs. (32.07±5.12)%, (9.75±3.16) ng/L vs. (6.44±3.05) ng/L, and 70.59% (12/17) vs. 32.58% (29/89)]; there were statistical differences (t=-6.068, -2.924, 5.774, and 4.077; χ²=8.692; all P<0.05). The logistic regression analysis showed that tumor stage and CD3⁺, CD8⁺, and IL-6 levels were the factors influencing the patients' prognosis (all P<0.05). The areas under the ROC's of CD3⁺, CD8⁺, and IL-6 for predicting the patients' adverse prognosis were 0.847, 0.853, and 0.768, respectively. Conclusions　In patients with gastric cancer, the levels of CD3⁺ and CD4⁺ are low, and the levels of CD8 ⁺ and IL-6 are high. The levels of CD3⁺, CD8⁺, and IL-6 affect the prognosis of patients with gastric cancer.

Key words:

Gastric cancer, Peripheral blood T lymphocyte subsets, Interleukin-6, Prognosis

周光婷王刚.

T淋巴细胞亚群、IL-6在胃癌患者中的表达及其与预后的相关性 [J]. 国际医药卫生导报, 2024, 30(15): 2585-2589.

Zhou Guangting, Wang Gang.

Expression of T lymphocyte subsets and IL-6 in patients with gastric cancer and their correlation with prognosis [J]. International Medicine and Health Guidance News, 2024, 30(15): 2585-2589.

参考文献

[1] Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives [J]. J Hematol Oncol, 2023, 16(1): 57. DOI: 10.1186/s13045-023-01451-3.
[2] Douda L, Cyrany J, Tachecí I. Early gastric cancer [J]. Vnitr Lek, 2022, 68(6):371-375. DOI: 10.36290/vnl.2022.077.
[3] Li WW, Jiao J, Wang ZY, et al. Clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer, its effect on nutritional status and Changes of peripheral blood T lymphocyte subsets [J]. Pak J Med Sci, 2021, 37(7): 1902-1907. DOI: 10.12669/pjms.37.7.4347.
[4] 姜兆志,禚志明,汤小龙,等. 外周血中性粒细胞/淋巴细胞比值与进展期胃癌患者新辅助化疗效果及预后的相关性分析[J]. 中国现代普通外科进展,2023,26(10):787-792. DOI:10.3969/j.issn.1009-9905.2023.10.007.
[5] 徐珍琴,胡艳,鲁恒珍,等. miR-26a、IL-17、Hcy在胃癌患者外周血中的表达及其与胃癌复发的关系[J]. 胃肠病学和肝病学杂志,2023,32(9):1006-1009,1014. DOI:10.3969/j.issn.1006-5709.2023.09.009.
[6] 刘琪,夏杰,冯以斌,等. 细菌性肝脓肿合并2型糖尿病患者外周血T淋巴细胞亚群表达水平与预后相关性分析[J]. 陕西医学杂志,2021,50(12):1510-1512,1516. DOI:10.3969/j.issn.1000-7377.2021.12.010.
[7] 李檬,徐艳霞,王燕楠,等. 外周血T淋巴细胞亚群及CRP水平与腺样体肥大合并阻塞性睡眠呼吸暂停低通气综合征患儿病情严重程度的相关性分析[J]. 中国卫生检验杂志,2023,33(19):2316-2318,2331.
[8] 郑宇,陈晋. 血清IL-6和胃蛋白酶原Ⅰ/Ⅱ比值对老年胃癌患者预后评估的价值[J]. 老年医学与保健,2022,28(1):120-124. DOI:10.3969/j.issn.1008-8296.2022.01.025.
[9] 刘慧敏,刘晓利,王欣惠,等. 原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义[J]. 实用肝脏病杂志,2022,25(2):255-258. DOI:10.3969/j.issn.1672-5069.2022.02.026.
[10] 应玲静,曹秀娟,陈美仙. 婴幼儿脓毒症外周血T淋巴细胞亚群表达及临床意义[J]. 中华医院感染学杂志,2022,32(21):3312-3316. DOI:10.11816/cn.ni.2022-220652.
[11] 寇飞,陈坤峰,赵志坚.急性期骨关节型布鲁菌病患者外周血CD4^(+)T淋巴细胞亚群的表达水平及意义分析[J].中国地方病防治,2022,37(1):89-90.
[12] 狄英波. 血清降钙素原C-反应蛋白白细胞介素-6表达及免疫功能变化在女性细菌感染性疾病中的临床意义[J]. 中国妇幼保健,2021,36(24):5643-5645. DOI: 10.19829/j.zgfybj.issn.1001-4411.2021.24.011.
[13] 张叶萌,张莹,张延霞. 慢性活动性EBV感染患者外周血淋巴细胞表达水平及预后危险因素分析[J]. 西部医学,2023,35(11):1699-1705,1710. DOI:10.3969/j.issn.1672-3511. 2023.11.026.
[14] 黄守秋,陈晓兵,李帆,等. T淋巴细胞亚群在脓毒症患者中的表达特点及预后的研究[J]. 医学研究杂志,2022,51(6):108-112,102. DOI:10.11969/j.issn.1673- 548X. 2022.06.024.
[15] 谢宇,包红雨,施小凤,等. 细胞因子及淋巴细胞亚群在弥漫大B细胞淋巴瘤患者中的表达及临床意义[J]. 中国实验血液学杂志,2023,31(4):1061-1068. DOI: 10.19746/j.cnki.issn1009-2137.2023.04.021.
[16] 许莉敏,谢燕. 外周血单核细胞DNMT1及血清IL-6在糖尿病肾脏病中的表达及意义[J]. 天津医药, 2023, 51(2): 194-198. DOI: 10.11958/20220812.